Literature DB >> 16455970

B cell tolerance checkpoints that restrict pathways of antigen-driven differentiation.

Jacqueline William1, Chad Euler, Nicole Primarolo, Mark J Shlomchik.   

Abstract

Autoreactive B cells can be regulated by deletion, receptor editing, or anergy. Rheumatoid factor (RF)-expressing B lymphocytes in normal mice are not controlled by these mechanisms, but they do not secrete autoantibody and were presumed to ignore self-Ag. Surprisingly, we now find that these B cells are not quiescent, but instead are constitutively and specifically activated by self-Ag. In BALB/c mice, RF B cells form germinal centers (GCs) but few Ab-forming cells (AFCs). In contrast, autoimmune mice that express the autoantigen readily generate RF AFCs. Most interestingly, autoantigen-specific RF GCs in BALB/c mice appear defective. B cells in such GCs neither expand nor are selected as efficiently as equivalent cells in autoimmune mice. Thus, our data establish two novel checkpoints of autoreactive B cell regulation that are engaged only after initial autoreactive B cell activation: one that allows GCs but prevents AFC formation and one that impairs selection in the GC. Both of these checkpoints fail in autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455970     DOI: 10.4049/jimmunol.176.4.2142

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells.

Authors:  Robin A Herlands; Sean R Christensen; Rebecca A Sweet; Uri Hershberg; Mark J Shlomchik
Journal:  Immunity       Date:  2008-08-15       Impact factor: 31.745

2.  A new site-directed transgenic rheumatoid factor mouse model demonstrates extrafollicular class switch and plasmablast formation.

Authors:  Rebecca A Sweet; Sean R Christensen; Michelle L Harris; Jonathan Shupe; Jaime L Sutherland; Mark J Shlomchik
Journal:  Autoimmunity       Date:  2010-04-07       Impact factor: 2.815

3.  Requirement for Transcription Factor Ets1 in B Cell Tolerance to Self-Antigens.

Authors:  Lisa Russell; Shinu John; Jaime Cullen; Wei Luo; Mark J Shlomchik; Lee Ann Garrett-Sinha
Journal:  J Immunol       Date:  2015-09-09       Impact factor: 5.422

4.  Spontaneous loss of tolerance of autoreactive B cells in Act1-deficient rheumatoid factor transgenic mice.

Authors:  Natalia V Giltiay; Yi Lu; Jaime L Cullen; Trine N Jørgensen; Mark J Shlomchik; Xiaoxia Li
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

5.  Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites.

Authors:  Robin A Herlands; Jacqueline William; Uri Hershberg; Mark J Shlomchik
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

6.  Anti-Sm B cell tolerance and tolerance loss in systemic lupus erythematosus.

Authors:  Stephen H Clarke
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 7.  The role of B cells in lupus pathogenesis.

Authors:  Emil Nashi; YingHua Wang; Betty Diamond
Journal:  Int J Biochem Cell Biol       Date:  2009-10-20       Impact factor: 5.085

8.  The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints.

Authors:  Raja Vuyyuru; Chandra Mohan; Tim Manser; Ziaur S M Rahman
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

9.  Activation of rheumatoid factor-specific B cells is antigen dependent and occurs preferentially outside of germinal centers in the lupus-prone NZM2410 mouse model.

Authors:  Allison Sang; Haitao Niu; Jaime Cullen; Seung Chul Choi; Ying Yi Zheng; Haowei Wang; Mark J Shlomchik; Laurence Morel
Journal:  J Immunol       Date:  2014-07-11       Impact factor: 5.422

10.  TLR4 signaling augments B lymphocyte migration and overcomes the restriction that limits access to germinal center dark zones.

Authors:  Il-Young Hwang; Chung Park; Kathleen Harrison; John H Kehrl
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.